Trial reportEBioMedicine2026
Early transcriptional responses following Ad26.COV2.S vaccination in individuals with prior SARS-CoV-2 infection.
Trial report in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAd26.COV2.S is a recombinant, replication-incompetent human adenovirus serotype 26 (Ad26) vectored vaccine encoding a full-length SARS-CoV-2 spike protein in a prefusion-stabilised conformation. The genes and pathways which are differentially regulated following vaccination with Ad26.COV2.S, how these differ over time, and under different regimens, have not been investigated.
methodsGene expression changes were profiled via RNAseq following the first and second dose of Ad26.COV2.S in a subset of individuals with pre-existing SARS-CoV-2 immunity due to prior SARS-CoV-2 infection, included in a randomised, double-blind, Phase 3 study (NCT#04908722). Transcriptional responses induced by a 1- and 2-dose regimen were assessed, each at two different dose levels: the marketed 5 × 10
findingsConsistent with other vaccine studies, antiviral, interferon, cytokine, and monocyte blood transcriptional modules were differentially regulated one day post-Ad26.COV2.S vaccination. At three days post-vaccination, innate immunity was still transcriptionally active at lower levels than one day post-vaccination. By seven days post-Ad26.COV2.S, increased immunoglobulin gene expression dominated the transcriptome response, indicating a shift towards humoural and B cell responses and activation of adaptive immunity. Transcriptional responses post-Ad26.COV2.S were generally stronger after the first dose versus the second dose.
interpretationIn this study in whole blood, innate and adaptive immune transcripts were upregulated as early as one and seven days post-Ad26.COV2.S, respectively. These findings add to the limited data on innate immune responses to adenovirus-based vaccines in a clinical setting and contribute to understanding the mechanisms behind the adaptive immune responses that may contribute to protective immunity.
fundingThis study was funded by Johnson & Johnson Innovative Medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.